Abstract
Overactive bladder (OAB) is a serious urination disorder which affects at least 17% of the population above 40 years old, of which 56% are women and 44% are men. M-cholinoblockers are the first line therapy and the main treatment for OAB. However, their side effects, along with low efficacy, force women to stop taking the drugs. Activation of beta-3-adrenergic receptors is known toreduce the tone of detrusor muscle in the bladder. This resulted in the invention of mirabegron (Mirabegron, Betmiga, Astellas Pharma Europe, Netherlands), the first drug of a new pharmacologic group (beta-3 adrenergic agonists) for the treatment of OAB. A selective beta-3 agonist, mirabegron has no side effects such as dry mouth, increased intraocular pressure or constipation. Numerous clinical studies demonstrated a reduction in the number of episodes of urinary incontinence and frequent urination in the mirabegron group compared to the placebo group.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
